1. Hantoushzadeh S, Behzadian A, Hasheminejad MM, Hasheminejad F, Helal Birjandi A, Akbari M, et al. Aspirin administration from early pregnancy versus initiation after 11 weeks of gestation for prevention of pre-eclampsia in high-risk pregnant women: Study protocol for randomized controlled trial. Int J Reprod BioMed 2024; 22: 69-80. [
DOI:10.18502/ijrm.v22i1.15244] [
PMID] [
PMCID]
2. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 2010; 116: 402-414. [
DOI:10.1097/AOG.0b013e3181e9322a] [
PMID]
3. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613-622. [
DOI:10.1056/NEJMoa1704559] [
PMID]
4. Ghesquiere L, Vachon-Marceau C, Kingdom JC, Ferreira E, Côté S, Guerby P, et al. Short communication: Is there any benefit of initiating aspirin before the 11th week of gestation? Pregnancy Hypertens 2022; 30: 189-191. [
DOI:10.1016/j.preghy.2022.10.009] [
PMID]
5. Chaemsaithong P, Cuenca-Gomez D, Plana MN, Gil MM, Poon LC. Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? Am J Obstet Gynecol 2020; 222: 437-450. [
DOI:10.1016/j.ajog.2019.08.047] [
PMID]
6. Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Manjunath Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): A randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 285-293. [
DOI:10.1016/S0140-6736(19)32973-3] [
PMID]
7. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011; 39: 641-652. [
DOI:10.1515/jpm.2011.098] [
PMID] [
PMCID]
8. Wright D, Tan MY, O'Gorman N, Syngelaki A, Nicolaides KH. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG 2022; 129: 1308-1317. [
DOI:10.1111/1471-0528.17096] [
PMID]
9. Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol Reprod Biol 2011; 157: 38-42. [
DOI:10.1016/j.ejogrb.2011.02.026] [
PMID]
10. Ghesquiere L, Guerby P, Marchant I, Kumar N, Zare M, Foisy MA, et al. Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023; 5: 101000. [
DOI:10.1016/j.ajogmf.2023.101000] [
PMID]
11. Demuth B, Pellan A, Boutin A, Bujold E, Ghesquière L. Aspirin at 75 to 81 mg daily for the prevention of preterm pre-eclampsia: Systematic review and meta-analysis. J Clin Med 2024; 13: 1022. [
DOI:10.3390/jcm13041022] [
PMID] [
PMCID]
12. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 110-120.e6. [
DOI:10.1016/j.ajog.2016.09.076] [
PMID]